相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Structural evidence for native state stabilization of a conformationally labile amyloidogenic transthyretin variant by fibrillogenesis inhibitors
Giuseppe Zanotti et al.
FEBS LETTERS (2013)
AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin
Sravan C. Penchala et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade
Christine E. Bulawa et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Enhanced expression of human cDNA by phosphoglycerate kinase promoter-puromycin cassette in the mouse transthyretin locus
Zhenghua Li et al.
TRANSGENIC RESEARCH (2011)
CHF5074, a Novel gamma-Secretase Modulator, Restores Hippocampal Neurogenesis Potential and Reverses Contextual Memory Deficit in a Transgenic Mouse Model of Alzheimer's Disease
Bruno P. Imbimbo et al.
JOURNAL OF ALZHEIMERS DISEASE (2010)
CHF5074, a novel γ-secretase modulator, attenuates brain β-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease
B. P. Imbimbo et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Pathogenesis of and Therapeutic Strategies to Ameliorate the Transthyretin Amyloidoses
Yoshiki Sekijima et al.
CURRENT PHARMACEUTICAL DESIGN (2008)
Inconsistency between hepatic expression and serum concentration of transthyretin in mice humanized at the transthyretin locus
Gang Zhao et al.
GENES TO CELLS (2008)
1-(3′,4′-dichloro-2-fluoro[1,1′-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel γ-secretase modulator, reduces brain β-amyloid pathology in a Transgenic mouse model of Alzheimer's disease without causing peripheral toxicity
Bruno P. Imbimbo et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
In vitro and in vivo profiling of CHF5022 and CHF5074 -: Two β-amyloid1-42 lowering agents
Bruno P. Imbimbo et al.
PHARMACOLOGICAL RESEARCH (2007)
Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis
Kana Tojo et al.
NEUROSCIENCE RESEARCH (2006)
Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis
Yoshiki Sekijima et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2006)
Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials
Patricia M. Kearney et al.
BMJ-BRITISH MEDICAL JOURNAL (2006)
Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: A focus on the transthyretin amyloidoses
SM Johnson et al.
ACCOUNTS OF CHEMICAL RESEARCH (2005)
Synthesis and biological activity of flurbiprofen analogues as selective inhibitors β-amyloid1-42 secretion
I Peretto et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Design, synthesis, and evaluation of oxazole transthyretin amyloidogenesis inhibitors
H Razavi et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2005)
A different amyloid formation mechanism: De novo oculoleptomeningeal amyloid deposits after liver transplantation
Y Ando et al.
TRANSPLANTATION (2004)
Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis
SL Adamski-Werner et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Hydroxylated polychlorinated biphenyls selectively bind transthyretin in blood and inhibit amyloidogenesis: Rationalizing rodent PCB toxicity
HE Purkey et al.
CHEMISTRY & BIOLOGY (2004)
Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants
SR Miller et al.
LABORATORY INVESTIGATION (2004)
Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization
NS Green et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2003)
Benzoxazoles as transthyretin amyloid fibril inhibitors: Synthesis, evaluation, and mechanism of action
H Razavi et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2003)
Sequence-dependent denaturation energetics:: A major determinant in amyloid disease diversity
P Hammarström et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
The evolution of transthyretin synthesis in the choroid plexus
G Schreiber
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2002)
Risk of cardiovascular events associated with selective COX-2 inhibitors
D Mukherjee et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
分享论文
